Innate Pharma Updates Share Capital and Voting Rights as of December 18, 2025

Innate Pharma SA ( (FR:IPH) ) has shared an announcement.

On December 22, 2025, Innate Pharma reported that as of December 18, 2025, it had 92,197,823 ordinary shares outstanding, alongside a small number of preferred shares from 2016 and 2017, resulting in 92,962,943 theoretical voting rights and 92,944,368 exercisable voting rights. The disclosure, made under French market regulations, provides investors and regulators with an updated view of the company’s share capital and voting structure, ensuring transparency for threshold calculations and governance monitoring as Innate continues to develop its oncology pipeline and maintain its dual listing in Paris and on Nasdaq.

The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. Leveraging antibody engineering and innovative target identification, the company is advancing a portfolio of potential first- or best-in-class antibody-based therapeutics, including the Nectin-4 ADC IPH4502 for solid tumors, the anti-KIR3DL2 antibody lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody being developed with AstraZeneca for non-small cell lung cancer. Listed on Euronext Paris and Nasdaq, Innate Pharma collaborates with major biopharmaceutical partners such as Sanofi and AstraZeneca, as well as academic institutions, to strengthen its position in the immuno-oncology market.

YTD Price Performance: -20.56%

Average Trading Volume: 266,965

Technical Sentiment Signal: Strong Sell

Current Market Cap: €141.4M

See more insights into IPH stock on TipRanks’ Stock Analysis page.